Phathom Pharmaceuticals (PHAT) Operating Leases (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Operating Leases for 8 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Leases rose 214.94% year-over-year to $1.9 million; the TTM figure through Jun 2026 stood at $1.9 million (up 214.94% YoY), while the FY2025 annual figure was $2.1 million, changed N/A from the prior year.
• Operating Leases retreated to $1.9 million in Q2 2026 per PHAT's latest filing, from $2.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $2.1 million in Q3 2025 and bottomed at $133000.0 in Q2 2024.
• Historically, Operating Leases has averaged $1.1 million across 5 years, with a median of $1.1 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Leases tumbled 83.14% — and 2025, when it jumped 342.86%.
• Phathom Pharmaceuticals' Operating Leases stood at $1.1 million in 2022, then slumped by 57.92% to $462000.0 in 2023, then slumped by 71.21% to $133000.0 in 2024, then jumped by 1452.63% to $2.1 million in 2025, then fell by 10.17% to $1.9 million in 2026.
• Business Quant data shows PHAT's Operating Leases at $1.9 million in Q2 2026, $2.0 million in Q1 2026, and $2.1 million in Q4 2025.